WallStSmart
ASRT

Assertio Therapeutics Inc

NASDAQ: ASRT · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$22.55
-0.04% today

Updated 2026-06-05

Market cap
$151.54M
P/E ratio
P/S ratio
1.48x
EPS (TTM)
$-5.55
Dividend yield
52W range
$9 – $23
Volume
0.3M

Assertio Therapeutics Inc (ASRT) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-25.59%
Operating margin
-14.51%
ROE
-47.19%
ROA
-5.71%
Debt/equity
0.53x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2006$9.55M$-39.66M83.24%-435.62%-415.23%
2007$65.58M$49.22M96.04%72.49%75.05%
2008$34.84M$-15.30M83.43%-49.06%-43.92%
2009$57.73M$-22.01M90.89%-38.23%-38.12%
2010$80.76M$3.90M89.97%4.49%4.82%
2011$132.97M$70.73M95.83%53.17%53.19%
2012$90.82M$-29.78M93.35%-33.42%-32.79%
2013$134.21M$43.31M94.72%6.94%32.27%
2014$390.36M$131.76M96.12%60.67%33.75%
2015$342.74M$-75.74M80.19%-14.71%-22.10%
2016$455.90M$-88.72M80.83%5.38%-19.46%
2017$380.72M$-102.50M80.93%-11.08%-26.92%
2018$311.77M$36.91M94.07%14.00%11.84%
2019$229.53M$-217.20M95.86%-84.71%-94.63%
2020$108.08M$-28.14M85.41%-76.02%-26.04%
2021$111.01M$-1.28M85.74%8.49%-1.15%
2022$156.23M$109.63M88.00%25.22%70.17%
2023$152.07M$-331.94M82.23%-160.15%-218.28%
2024$124.96M$-21.58M68.61%-19.59%-17.27%
2025$118.71M$-30.38M44.92%-14.51%-25.59%

Frequently asked questions

What is Assertio Therapeutics Inc's revenue?

Assertio Therapeutics Inc's trailing twelve-month revenue is $102.16M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is ASRT?

In its most recent fiscal year, ASRT ran a gross margin of 44.92%, an operating margin of -14.51%, and a net margin of -25.59%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ASRT generate?

ASRT produced $-28.18M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ASRT's balance sheet healthy?

ASRT holds $10.23M in cash and equivalents against $39.12M in long-term debt, on $93.95M of shareholder equity. That debt is best read against the cash flow the business throws off each year.